BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23590397)

  • 1. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
    Torres A; Mouton JW; Pea F
    Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: drug evaluation and place in therapy.
    Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
    Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
    [No Abstract]   [Full Text] [Related]  

  • 10. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
    Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
    Kaye KS; Udeani G; Cole P; Friedland HD
    Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD; Gums JG
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.
    Chung DR; Song JH; Kim SH; Thamlikitkul V; Huang SG; Wang H; So TM; Yasin RM; Hsueh PR; Carlos CC; Hsu LY; Buntaran L; Lalitha MK; Kim MJ; Choi JY; Kim SI; Ko KS; Kang CI; Peck KR;
    Am J Respir Crit Care Med; 2011 Dec; 184(12):1409-17. PubMed ID: 21920919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.
    Barbier F; Andremont A; Wolff M; Bouadma L
    Curr Opin Pulm Med; 2013 May; 19(3):216-28. PubMed ID: 23524477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bradley JS
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S136-43. PubMed ID: 20597664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
    Rouse MS; Hein MM; Anguita-Alonso P; Steckelberg JM; Patel R
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):333-6. PubMed ID: 16631339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.